Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Pfizer Inc. (NYSE:PFE) and BioNTech SE – ADR announced an agreement with the U.S. government Wednesday to supply an initial consignment of 100 million doses of the coronavirus vaccine the companies are developing in the event of future emergency use authorization or full approval for the shot.
US Government Deal Positive For Pfizer: Pfizer's deal is positive for the nation as well as the company, BofA Securities analyst Geoff Meacham said in a note.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The U.S. government has the optionality to acquire an additional 500 million doses the analyst said. Assuming a two-dose regimen, 600 million doses could cover over 90% of the U.S. population, he said.
For Pfizer, the vaccine news is a positive development, Meacham said.
That said, the analyst does not see the vaccine programs as being fully derisked is looking ahead to additional data as Phase 3 trials get underway.
Pfizer's Vaccine Economics: At the $20 price point implied by the U.S. government's contract value and assuming a 50-50 gross profit split between Pfizer and BioNTech, Meacham expects the vaccine to be helpful to Pfizer's P&L.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
This is especially true as company contends with portfolio risks that include the adjuvant Ibrance failure, recent pipeline programs that failed to stand apart from competition and the Eliquis patent ruling, the analyst said.
Pfizer shares have added about $30 billion in value since their recent low in June, mainly on COVID-19 news. The valuation implies about 1.5 billion doses sold at the $20 price point, Meacham said.
To justify the valuation, Pfizer may have to sell about 6 billion doses at a 50% margin, according to BofA — more than the sell-side firm's assumed number of patients treated worldwide through 2030 .
PFE Rating, Price Action: Meacham maintained a Neutral rating on Pfizer with a $38 price target.
At last check, Pfizer shares were down 0.18% at $38.49.
Related Links:
Intel, Texas Instruments To Kickstart Chip Earnings With 'Better-Than-Feared' Results
Nvidia Analysts See Multibillion-Dollar Opportunity In Automated Driving Deal With Mercedes-Benz
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.